Literature DB >> 23299778

Efficient allocation of novel agents in multiple myeloma: a work in progress.

Jennifer G Gaultney1, Carin A Uyl-de Groot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23299778      PMCID： PMC3556256          DOI： 10.1634/theoncologist.2012-0484

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  34 in total

Review 1.  Presentation and risk stratification--improving prognosis for patients with multiple myeloma.

Authors:  Sagar Lonial
Journal:  Cancer Treat Rev       Date:  2010-05       Impact factor: 12.111

Review 2.  Novel therapeutic targets for multiple myeloma.

Authors:  Anuj Mahindra; Diana Cirstea; Noopur Raje
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

3.  The climbing costs of cancer care.

Authors:  Norra Macready
Journal:  J Natl Cancer Inst       Date:  2011-09-20       Impact factor: 13.506

Review 4.  Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology.

Authors:  Jennifer G Gaultney; W K Redekop; Pieter Sonneveld; Carin A Uyl-de Groot
Journal:  Eur J Cancer       Date:  2011-05-09       Impact factor: 9.162

5.  Healthcare costs of multiple myeloma: an Italian study.

Authors:  D Koleva; S Cortelazzo; C Toldo; L Garattini
Journal:  Eur J Cancer Care (Engl)       Date:  2011-05       Impact factor: 2.520

6.  Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.

Authors:  X Armoiry; F Fagnani; L Benboubker; T Facon; J P Fermand; C Hulin; P Moreau; G Aulagner
Journal:  J Clin Pharm Ther       Date:  2011-02       Impact factor: 2.512

7.  The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research.

Authors:  David Meltzer; Anirban Basu; Rena Conti
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.

Authors:  John Hornberger; Joseph Rickert; Ravinder Dhawan; Johan Liwing; Johan Aschan; Mikael Löthgren
Journal:  Eur J Haematol       Date:  2010-12       Impact factor: 2.997

9.  Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.

Authors:  Jörgen Möller; Lars Nicklasson; Ananthram Murthy
Journal:  J Med Econ       Date:  2011-09-05       Impact factor: 2.448

10.  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Kim Cocks; Sue E Bell; Alex J Szubert; Nuria Navarro-Coy; Mark T Drayson; Roger G Owen; Sylvia Feyler; A John Ashcroft; Fiona Ross; Jennifer Byrne; Huw Roddie; Claudius Rudin; Gordon Cook; Graham H Jackson; J Anthony Child
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321
View more
  3 in total

1.  The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan.

Authors:  Jeng-Shiun Du; Yi-Chun Kuo; Hon-Yi Shi; Ming-Chung Wang; Li-Ying Wang; Tzer-Ming Chuang; Ya-Lun Ke; Tsung-Jang Yeh; Yu-Ching Gau; Hui-Ching Wang; Shih-Feng Cho; Samuel Yien Hsiao; Yi-Chang Liu; Chin-Mu Hsu; Hui-Hua Hsiao
Journal:  J Pers Med       Date:  2022-01-19

2.  Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.

Authors:  Sarah Gooding; I-Jun Lau; Mimi Sheikh; Pamela Roberts; Julia Wong; Emmy Dickens; Ash Bullement; Jamie Elvidge; Dawn Lee; Karthik Ramasamy
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

3.  Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia.

Authors:  Đurđa Vukićević; Ursula Rochau; Aleksandar Savić; Monika Schaffner; Milica Jevđević; Igor Stojkov; Gaby Sroczynski; Wolfgang Willenbacher; Beate Jahn; Uwe Siebert
Journal:  Zdr Varst       Date:  2020-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.